Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that it has appointed Brendan P. Rae, Ph.D., J.D., to the position of Chief Business Officer, effective November 1, 2011. In this role, Dr. Rae will lead the Company's licensing and business development efforts with a focus on establishing corporate partnerships and strategic alliances worldwide.

Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer

Pasadena, CA | Posted on November 3rd, 2011

In addition to practicing patent law, Dr. Rae has worked as a licensing and business development professional in the pharmaceutical and biotechnology industries over the last 15 years. In this capacity, he has successfully sourced new products, led due diligence and commercial evaluation teams, and negotiated and executed agreements in the US, Europe and Far East. Most recently, Dr. Rae was the Chief Business Officer of Vivaldi Biosciences Inc., an influenza vaccine development company headquartered in New York City. Prior to that, he served, from 2005 to 2010, as Senior Vice President, Licensing and Business Development at VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of therapies for the treatment of cardiovascular disease. Dr. Rae's pharmaceutical licensing experience was gained at Hoffman-La Roche Ltd., where he directed the company's in-licensing and out-licensing activities from 1996 to 2003, and at Purdue Pharma L.P. Dr. Rae practiced patent law at the firm of Amster, Rothstein & Ebenstein, LLP.

"Establishing this role is a key element in our strategy to build long-term value for our shareholders through a combination of in-house R&D and strategic partnership agreements," said Dr. Christopher Anzalone, President and Chief Executive Officer of Arrowhead. "Brendan's in-depth knowledge of and expertise in business development for biotechnology and pharmaceuticals companies will serve the Company well as we work to advance and partner our drug candidates. On behalf of our management and Board, I welcome Brendan to our team."

Dr. Rae added, "Arrowhead has established a comprehensive and advanced portfolio of leading RNAi technology and IP, which firmly positions the Company as a likely candidate for large industry partnerships. I am excited to join the Arrowhead team and look forward to playing an active role in helping the Company build on its success."

Dr. Rae obtained his Bachelor of Science degree in Microbiology from Glasgow University, and was awarded a Ph.D. by the Institute of Virology in Glasgow, Scotland. He was a Postdoctoral Fellow at the Roche Institute of Molecular Biology. Dr. Rae has served as an Adjunct Assistant Professor, Department of Microbiology and Immunology, at the New York Medical College since 1989, and a Visiting Professor in the School of Host Infection and Immunity at Liverpool University since 2008. Dr. Rae earned his Juris Doctor degree from Seton Hall Law School in Newark, New Jersey.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapies at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to .

NASDAQ Notice

As an inducement to his entering into employment with the Company, Dr. Rae was awarded an "inducement" option under the NASDAQ Marketplace Rules. The option entitles Dr. Rae to purchase, outside of the Company's stockholder approved equity incentive plans, an aggregate of up to 175,000 shares of the Company's common stock at an exercise price per share equal to the last reported closing price of the Company's common stock on the date of grant. The option vests and becomes exercisable over a period of four years from the date of grant.

Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Investor Relations Contact:
Brandi Floberg or Kathy Price
The Piacente Group, Inc.
212-481-2050

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Tissue regeneration using anti-inflammatory nanomolecules August 22nd, 2014

A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy August 22nd, 2014

Ultra-short pulse lasers & Positioning August 21st, 2014

Malvern’s Dr Alan Rawle talks TLAs in plenary lecture at Particulate Systems Analysis conference August 21st, 2014

Nanomedicine

Tissue regeneration using anti-inflammatory nanomolecules August 22nd, 2014

Ultra-short pulse lasers & Positioning August 21st, 2014

Nanotechnology Helps Production of Super Adsorbent Polymers August 21st, 2014

Newly-Developed Nanobiosensor Quickly Diagnoses Cancer August 20th, 2014

Announcements

Tissue regeneration using anti-inflammatory nanomolecules August 22nd, 2014

A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy August 22nd, 2014

Malvern’s Dr Alan Rawle talks TLAs in plenary lecture at Particulate Systems Analysis conference August 21st, 2014

Water window imaging opportunity: A new theoretical study elucidates mechanisms that could help in producing coherent radiations, ultimately promoting high-contrast imaging of biological samples August 21st, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Nanometrics CFO to Resign for New Job Opportunity August 8th, 2014

California Nanotechnologies Appoints Dr. Enrique Lavernia to the Board August 6th, 2014

ACS Biomaterials Science & Engineering™: Brand-new journal names editor July 29th, 2014

Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE